1-855-378-42281-855-378-4228
One of the out-patient treatment options for people in Blue Island battling with opioid dependence and addiction is called opioid maintenance therapy. Licensed clinics and doctors are certified to give specific meds to opioid dependent clients, many of which are opioids themselves and are addictive. In low amounts however, the individual does not experience being high but also does not experience acute cravings and isn't in opioid withdrawal. Methadone is the first drug tried for this sole purpose, but there are a few more choices currently to pick from.
Methadone is an opioid and can be taken at an out-patient clinic licensed to dispense the med, that is taken daily in liquid or pill form. The price of the med is approximately one hundred and fifty dolloars a month. Buprenorphine is also an opioid based med, and is in pill form often taken one day on, one day off. But unlike Methadone that is only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The cost monthly of buprenorphine is about three hundred dollars /month for the generic of the med. There is also a type of buprenorphine that contains naloxone, that is a med which reverses the effects of opiates. A person consuming this version of the drug, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and costs approximately $450 monthly. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other medications mentioned here it's an opioid blocker and isn't an opiate. A person has the choice to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents an individual from getting high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Treatment Centers In Blue Island, Click Here.
